Natco Pharma Ltd (NATCOPHARM) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow Natco Pharma Ltd reported sales of ₹735 Cr, operating profit of ₹186 Cr (OPM 25%) and net profit of ₹206 Cr for the quarter ended Jun 2026. Figures in ₹ crore, consolidated where available.
NATCOPHARM quarterly results (₹ Cr) Metric Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sales 1,371 475 1,221 1,329 1,363 647 739 735 Expenses 567 436 673 758 784 489 612 549 Operating Profit 804 39 548 571 579 159 128 186 OPM 59% 8% 45% 43% 42% 25% 17% 25% Other Income 64 176 66 62 100 58 78 59 Interest 4 4 10 3 13 10 11 13 Depreciation 46 47 98 58 52 46 50 47 Profit before tax 818 164 506 572 614 161 144 186 Tax 17% 19% 20% 16% 16% 13% -62% 34% Net Profit 676 132 406 480 518 151 269 206 EPS in Rs 37.81 7.43 22.7 26.84 28.94 8.46 14.96 11.53
NATCOPHARM profit & loss, annual (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM Sales 1,945 2,707 3,999 4,430 4,078 3,485 Expenses 1,681 1,772 2,245 2,234 2,642 2,433 Operating Profit 264 936 1,754 2,196 1,436 1,052 OPM 14% 35% 44% 50% 35% 30% Other Income 99 105 126 354 298 295 Interest 18 14 19 24 37 46 Depreciation 143 164 187 235 207 196 Profit before tax 202 862 1,674 2,291 1,491 1,104 Tax 16% 17% 17% 18% 8% - Net Profit 170 715 1,388 1,883 1,418 1,145 EPS in Rs 9.31 39.18 77.51 105.26 79.2 63.89 Dividend Payout 48% 14% 12% 6% 6% -
NATCOPHARM balance sheet (₹ Cr) Metric Mar 2023 Mar 2024 Mar 2025 Sep 2025 Mar 2026 Equity Capital 36 36 36 36 36 Reserves 4,837 5,817 7,571 8,614 9,185 Borrowings 167 371 279 261 714 Other Liabilities 617 682 744 1,520 1,139 Total Liabilities 5,657 6,906 8,631 10,430 11,074 Fixed Assets 2,427 2,491 2,698 2,697 2,803 CWIP 64 137 225 255 294 Investments 392 539 474 774 3,127 Other Assets 2,774 3,739 5,234 6,704 4,850 Total Assets 5,657 6,906 8,631 10,430 11,074
NATCOPHARM cash flows (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Cash from Operating Activity 46 849 1,212 1,697 1,768 Cash from Investing Activity 4 -465 -1,026 -1,436 -2,082 Cash from Financing Activity 35 -363 -247 -211 298 Net Cash Flow 85 21 -62 50 -16 Free Cash Flow -142 674 855 1,300 1,379 CFO/OP 36% 110% 85% 94% 151%
NATCOPHARM ratios Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Debtor Days 116 115 109 103 79 Inventory Days 496 432 357 405 480 Days Payable 105 153 120 145 216 Cash Conversion Cycle 507 394 345 362 343 Working Capital Days 256 198 151 151 163 ROCE 4% 18% 30% 33% 17%